News and Announcements
Actinogen Medical Congratulates Professor Colin Masters
- Published February 06, 2017 2:49PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
During Australia Day celebrations for 2017, Actinogen Medical were congratulating Professor Colin Masters on being appointed an Officer in regards to the General Division of the Order of Australia for:
“Distinguished service to medical research through international and national contributions to understanding Alzheimer’s and other neurogenerative diseases”.
This outstanding achievement, that Professor Masters has attained was announced as “Australia Day Honour”. Currently, Professor Masters is on Actinogen Medical, Xanamem™ Clinical Advisory Board, with also being the Executive Director of the Mental Health Institute, finally taking a position on at the University of Melbourne as a Laureate Professor. Professor Marsters, is also a Senior Deputy Director of the Florey Institute of Neuroscience and Mental Health, and a consultant at the Royal Melbourne Hospital. He has focused much of his career around research for Alzheimer’s disease and other neurodegenerative diseases. With over 35 years’ experience, he is widely acknowledged, globally, for his influence during research on the disease.
Company Updates
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
Backed By Leading Investment Groups and Family Offices
